Nintedanib Onkogen

Nintedanib, the active ingredient in Nintedanib Onkogen, is a tyrosine kinase inhibitor presented as an oral formulation for oral use. It is indicated for the treatment of idiopathic pulmonary fibrosis, non‑small cell lung cancer, and other solid tumours in adult patients.

GNH USA supplies Nintedanib Onkogen as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, oncology centres, pharmacies and clinics worldwide, with a focus on quality assurance, regulatory compliance, and reliable logistics to meet global demand across diverse therapeutic areas.

Nintedanib is used in diseases characterized by fibrosis or uncontrolled cell growth, targeting pathways that drive tissue scarring and tumor angiogenesis. These approved indications reflect the drug’s antifibrotic and antineoplastic properties demonstrated in clinical trials.

Idiopathic pulmonary fibrosis: slows disease progression by reducing fibroblast activity and extracellular matrix deposition. Non‑small cell lung cancer: inhibits tumor angiogenesis and proliferation, contributing to disease control in eligible patients. Other solid tumours: may be employed as part of combination regimens to limit tumour vascularisation and growth.

Nintedanib may cause a range of adverse reactions, varying from mild to severe.

Common Side Effects: - Nausea: feeling of sickness that may lead to reduced oral intake. - Diarrhea: frequent loose stools, sometimes requiring hydration. - Vomiting: episodes of expelling stomach contents. - Decreased appetite: reduced desire to eat, potentially affecting weight.

Serious or Rare Side Effects: - Hepatotoxicity: elevated liver enzymes or liver injury requiring monitoring. - Arterial thromboembolism: blood clots in arteries that can cause stroke or heart attack. - Severe bleeding: gastrointestinal or other bleeding events. - Gastrointestinal perforation: hole formation in the stomach or intestines.

When prescribing Nintedanib, clinicians should observe several precautionary measures to minimise risks. - Liver function monitoring: assess baseline enzymes and repeat periodically during therapy. - Cardiovascular assessment: evaluate for history of arterial events before initiating treatment. - Bleeding risk evaluation: avoid use in patients with active bleeding or uncontrolled anticoagulation. - Gastrointestinal surveillance: monitor for signs of perforation or severe abdominal pain. - Renal function consideration: adjust use in severe renal impairment as advised. - Store at below 25°C: keep in the original packaging, protect from moisture and light.

Nintedanib can interact with other medicines, altering its efficacy or safety profile.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors: may increase nintedanib exposure and risk of toxicity. - Anticoagulants (e.g., warfarin): combined use can heighten bleeding risk.

Moderate Interactions (Monitor Closely): - Moderate CYP3A4 inducers: may reduce drug levels and effectiveness. - P-glycoprotein substrates: concurrent use may affect plasma concentrations. - NSAIDs or antiplatelet agents: increase potential for gastrointestinal bleeding.